Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study.
FibroScan®
controlled attenuation parameter
metformin
non-alcoholic fatty liver disease
sodium-glucose cotransporter inhibitors
type 2 diabetes
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
31
12
2022
revised:
18
01
2023
accepted:
20
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) comprises a heterogeneous group of metabolic liver diseases and is characterized by the presence of steatosis in at least 5% of hepatocytes. The aim of our study was to assess the effect of the combination therapy of empagliflozin + metformin vs. metformin monotherapy on NAFLD progression in type 2 diabetic (T2DM) patients. Sixty-three metformin-treated T2DM patients who were SGLT2i-naïve and had an ultrasound diagnosis of NAFLD (aged 60.95 ± 11.14 years; males, 57.1%) were included in the present analysis. Thirty-three started the combination therapy. All patients were observed for 6 months and routinely monitored with anthropometry, blood biochemistry, and FibroScan
Identifiants
pubmed: 36830859
pii: biomedicines11020322
doi: 10.3390/biomedicines11020322
pmc: PMC9952909
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5155-5163
pubmed: 28051253
Metabolism. 2019 Sep;98:iii-ix
pubmed: 31301336
Diabetes Ther. 2021 Mar;12(3):843-861
pubmed: 33586120
Diabetes Care. 2018 Aug;41(8):1801-1808
pubmed: 29895557
Diabetes Obes Metab. 2019 Feb;21(2):285-292
pubmed: 30178600
Metabolism. 2015 Jan;64(1):5-12
pubmed: 25467841
Diabetologia. 2018 Oct;61(10):2155-2163
pubmed: 30066148
J Clin Med. 2020 Jan 18;9(1):
pubmed: 31963648
Mol Med. 2012 Feb 10;18:10-8
pubmed: 21979752
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420
Physiol Behav. 2008 Aug 6;94(5):637-42
pubmed: 18501391
Metabolism. 2015 Jan;64(1):60-78
pubmed: 25456097
J Am Coll Cardiol. 2000 Jul;36(1):219-26
pubmed: 10898438
Diabetes Res Clin Pract. 2020 Feb;160:108025
pubmed: 31954752
Acta Endocrinol (Buchar). 2020 Jan-Mar;16(1):59-67
pubmed: 32685040
Biomedicines. 2020 Dec 22;9(1):
pubmed: 33375185
Rev Cardiovasc Med. 2021 Sep 24;22(3):755-768
pubmed: 34565074
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Diabetologia. 2018 Sep;61(9):1923-1934
pubmed: 29971527
J Viral Hepat. 2012 Apr;19(4):244-53
pubmed: 22404722
Int J Mol Sci. 2018 Sep 21;19(10):
pubmed: 30241400
Front Endocrinol (Lausanne). 2022 Jan 31;12:739875
pubmed: 35173677
Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):3993-5
pubmed: 26592818
Metabolites. 2020 Dec 30;11(1):
pubmed: 33396949
Nat Commun. 2014 Oct 13;5:5190
pubmed: 25307742
J Biol Chem. 2004 Feb 6;279(6):4292-304
pubmed: 14625304
Sci China Life Sci. 2019 Nov;62(11):1420-1458
pubmed: 31686320
Diabetes Metab. 2016 Feb;42(1):25-32
pubmed: 26575250
Int J Mol Sci. 2022 Mar 26;23(7):
pubmed: 35409011
Antioxidants (Basel). 2021 Feb 10;10(2):
pubmed: 33578702
Gastroenterology. 2002 May;122(5):1399-410
pubmed: 11984526
Biomedicines. 2021 Sep 29;9(10):
pubmed: 34680473
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143
pubmed: 34964831
Endocrinol Metab (Seoul). 2018 Sep;33(3):387-394
pubmed: 30229578
Diabetes Obes Metab. 2020 Dec;22(12):2408-2416
pubmed: 32761721
Hepatology. 2005 Dec;42(6):1339-48
pubmed: 16317688
Diseases. 2020 May 11;8(2):
pubmed: 32403420
Diabetes Metab Res Rev. 2021 Sep;37(6):e3413
pubmed: 33010191
Front Med (Lausanne). 2021 Jun 30;8:695792
pubmed: 34277669
Diabetes Obes Metab. 2001 Feb;3(1):33-40
pubmed: 11213597
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Nutr Metab Cardiovasc Dis. 2021 Jul 22;31(8):2345-2353
pubmed: 34053830